Several Kun technology refinancing three types of certificates and capital to accelerate the value of medical AI landing

December 28, Skun Technology announced the completion of a new round of 590 million yuan financing. This round of financing by Sequoia Capital China Fund led investment, China Re insurance, Zhongjin Pucheng investment, old shareholders Huagai Capital, Wuyuan Capital, Genesis partner CCV, Qiming Venture Capital, Yuanyi Capital continue to follow investment. It is reported that since this year, the cumulative financing amount of several Kun technology reached nearly 1 billion yuan.In November 2020, the heart AI of the number of Kun was approved NMPA three-class certificate, becoming the first certificate in the field of narrow AI of the heart, but also the number of kun "digital heart" product family of the first three-class certificate.According to public data, the number of cardiovascular diseases in China now reachs 330 million, and the number may increase as the aging ages. "Digital heart" product family as an intelligent platform around the heart scene, its next 8 products have covered health screening, in-hospital accurate diagnosis, preoperative accurate assessment, out-of-hospital follow-up of the whole disease cycle, has been in public hospitals, private hospitals, regional medical service centers and other medical institutions at all levels of commercial use, a cumulative service of tens of millions of people.Among them, "Digital Brain" made its global debut in July 2020, focusing on 13 million stroke patients. In September 2020, a multi-center study conducted by Skun and Xuanwu Hospital was published in the Nature series of journals."The vision of Several Kun is to provide smart healthcare services everywhere," said Ma Chunxuan, CEO of Several Kun Technologies. Medical care is a new industry to drive, but also a need for patience and sustained cultivation of the industry, the intelligent path of the medical industry is even more challenging. Since its establishment in 2017, we have achieved breakthrough innovation in scientific research, product, approval, business and other aspects. Looking back over the past three years, the initial heart of the return to clinical nature, the creation of real value, and the need to address the pain point has never changed.It is learned that this round of financing will be used to increase research and development investment in the original research technology, continue to improve the "digital human body" core technology product line, further accelerate the deployment of products at all levels of medical institutions, accelerate the digital medical productivity in the national hospital intelligent construction process of comprehensive coverage. (Biological exploration)